A case of relapsing neuromyelitis optica treated with glatiramer acetate [5]

Journal of Neurology

Volumn 250, Issue 3, 2003, Pages 359-361

  Bergamaschi, Roberto ^a   Uggetti, Carla ^a   Tonietti, Simone ^a   Egitto, Maria Grazia ^a   Cosi, Vittorio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; STEROID;

ADULT; BRAIN; CASE REPORT; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; LETTER; LIVER FAILURE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPTIC NERVE; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REMISSION; SIDE EFFECT; SPINAL CORD; STEROID THERAPY; VISUAL IMPAIRMENT;

ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; NEUROMYELITIS OPTICA; PEPTIDES; RECURRENCE; SPINAL CORD;

EID: 0347295914     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-0979-2     Document Type: Letter

References (11)

1. Fazekas F, Offenbacher H, Schmidt R, Strasser-Fuchs S (1994) MRI of neuromyelitis optica: evidence for a distinct entity. J Neurol Neurosurg Psychiatry 57:1140-1142
2. Filippi M, Rocca MA, Moiola L, Martinelli V, Ghezzi A, Capra R, Salvi F, Comi G (1999) MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology 53:1705-1710
3. Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, Martin R (2000) Mechanisms of immunomodulation by glatiramer acetate. Neurology 55:1704-1714
4. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50:701-708
5. Leys D, Petit H, Block AM, Docx B, Basin B, Hache JC (1987) Neuromyélite optique de Devic. Rev Neurol (Paris) 11:722-728
6. Mandler RN, Ahmed W, Dencoff JE (1998) Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51:1219-1220
7. Mandler RN, Davis LE, Jeffery DR, Kornfeld M (1993) Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 34: 162-168
8. Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, Rosenberg GA (2001) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain 493-498
9. O'Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, McDonald WI, Miller DH (1996) Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 60:382-387
10. Piccolo G, Franciotta DM, Camana C, Bergamaschi R, Banfi P, Sandrini G, Citterio A (1990) Devic's neuromyelitis optica: long term follow-up and serial CSF findings in two cases. J Neurol 237:262-264
11. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53:1107-1114